Role of rRNA Modifications in Dyskeratosis Congenita
Role of rRNA Modifications in Dyskeratosis Congenita
批准号:
7130793
负责人:
Davide Ruggero
金额:
$42.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-01 至 2010-05-31
关键词:
bioinformaticsbioluminescencecell cycle proteinsdensity gradient ultracentrifugationenzyme inhibitorsgene mutationgenetic disordergenetic regulatory elementgenetic translationgenetically modified animalshigh throughput technologyimaging /visualization /scanninglaboratory mousemessenger RNAnuclear proteinspolysomesposttranslational modificationsprotein biosynthesisprotein kinaseproteomicsreporter genesribosomal RNAtumor suppressor genesuracil nucleoside
中文摘要
描述(由申请人提供):
英文摘要
DESCRIPTION (provided by applicant):
The long-term objective of this proposal is to elucidate the molecular and cellular basis for X-linked Dyskeratosis Congenita (X-DC), an inherited disease characterized by early mortality due to bone marrow failure as well as increased tumor susceptibility. The gene found mutated in X-DC, Dyskeratosis Congenita 1 (DKC1), is a pseudouridine synthase that mediates post-transcriptional modification of ribosomal RNA (rRNA) of both large and small ribosomal subunits through conversion of the uridine nucleotide (U) to pseudouridine (psi). The role of rRNA modifications in ribosome function and protein synthesis is poorly understood. We have generated DKC1 hypomorphic mice (DKC1m), which faithfully recapitulate all the clinical features of X-DC and are the first mouse model for severe aplastic anemia, a life threatening disease present in a heterogeneous group of disorders characterized by the failure in forming blood cells. DKC1m mice, also show increased cancer susceptibility and more than 50% of these animals develop carcinomas and B-cell lymphomas. We have shown that primary cells from DKC1m mice possess impairments in rRNA pseudouridylation and display decreased ribosome activity prior to disease onset. As outlined in the preliminary studies section, we have successfully utilized a proteomics strategy to identify a subset of mRNAs that are translationally impaired in DKC1m cells. These findings support a role for rRNA modifications in translation initiation of specific mRNAs, which harbor an internal ribosome entry site (IRES) positioned in their 5'UTR (5'untraslated region). The goals of the proposed study are to investigate the role of dyskerin and rRNA modification in control of protein synthesis. In addition, utilizing a molecular and genetic approach we will monitor translation regulation in vivo in DKC1m mice and genetically test the functional consequences of translational impairments in key target mRNAs towards the pathological features of X-DC. In Aim 1 we will expand on our proteomics strategy to characterize mRNAs, which rely on dyskerin activity and rRNA modifications for translation initiation. In Aim 2 we will define, in vivo, the role of defective IRES-dependent translation in X-DC pathogenesis utilizing a genetic approach as well as a novel live imaging system to follow IRES-dependent translation. Finally, in Aim 3 we will determine the molecular step(s) in which DKC1m ribosomes fail to initiate protein synthesis utilizing an in vitro reconstituted system. Lay abstract. Together these studies will build a deeper foundation for understanding the key genetic and molecular events that cause X-DC human disease and provide new animal models that will be vital for understanding the underlying causes of bone marrow failure and cancer susceptibility.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ERa is a novel RNA-binding protein controlling breast cancer
-
批准号:10580061
-
项目类别:
-
资助金额:$46.88万
-
财政年份:2022
-
负责人:Davide Ruggero
-
依托单位:
ERa is a novel RNA-binding protein controlling breast cancer
-
批准号:10460857
-
项目类别:
-
资助金额:$47.84万
-
财政年份:2022
-
负责人:Davide Ruggero
-
依托单位:
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications
-
批准号:10522626
-
项目类别:
-
资助金额:$66.62万
-
财政年份:2022
-
负责人:Davide Ruggero
-
依托单位:
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications
-
批准号:10672311
-
项目类别:
-
资助金额:$66.62万
-
财政年份:2022
-
负责人:Davide Ruggero
-
依托单位:
Mechanisms of regulated translation control in cancer and its therapeutic implications
-
批准号:10664866
-
项目类别:
-
资助金额:$94.96万
-
财政年份:2019
-
负责人:Davide Ruggero
-
依托单位:
Mechanisms of regulated translation control in cancer and its therapeutic implications
-
批准号:10226938
-
项目类别:
-
资助金额:$96.9万
-
财政年份:2019
-
负责人:Davide Ruggero
-
依托单位:
Mechanisms of regulated translation control in cancer and its therapeutic implications
-
批准号:10436946
-
项目类别:
-
资助金额:$94.96万
-
财政年份:2019
-
负责人:Davide Ruggero
-
依托单位:
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer
-
批准号:9265424
-
项目类别:
-
资助金额:$36.68万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer
-
批准号:8674344
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
MYCN, mTOR and translation control in medulloblastoma
-
批准号:9304355
-
项目类别:
-
资助金额:$60.35万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
Diversity Supplement for MYCN, mTOR and translation control in medulloblastoma
-
批准号:9067800
-
项目类别:
-
资助金额:$1.82万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
MYCN, mTOR and translation control in medulloblastoma
-
批准号:8801526
-
项目类别:
-
资助金额:$63.22万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer
-
批准号:8842956
-
项目类别:
-
资助金额:$38.14万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
Deciphering the role of the translational oncogenic program in Prostate Cancer
-
批准号:9403874
-
项目类别:
-
资助金额:$41.91万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
RIBOSOMAL RNA SEQUENCE ANALYSIS
-
批准号:8363850
-
项目类别:
-
资助金额:$1.19万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
-
批准号:8515756
-
项目类别:
-
资助金额:$40.97万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
-
批准号:8187270
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
-
批准号:8919267
-
项目类别:
-
资助金额:$35.31万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
-
批准号:8703036
-
项目类别:
-
资助金额:$34.41万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
-
批准号:8323911
-
项目类别:
-
资助金额:$43.04万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
海外基金